Mimedx Group, Inc. (MDXG)

$7.565

-0.18

(-2.39%)▲

Market is closed - opens 7 PM, 29 Sep 2023

Insights on Mimedx Group, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 74.37M → 66.88M (in $), with an average decrease of 5.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -2.11M → -10.86M (in $), with an average decrease of 127.0% per quarter

Performance

  • $7.50
    $7.80
    $7.57
    downward going graph

    0.92%

    Downside

    Day's Volatility :3.85%

    Upside

    2.95%

    downward going graph
  • $2.43
    $8.60
    $7.57
    downward going graph

    67.9%

    Downside

    52 Weeks Volatility :71.74%

    Upside

    11.98%

    downward going graph

Returns

PeriodMimedx Group, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
20.72%
-1.1%
0.0%
6 Months
132.73%
1.6%
0.9%
1 Year
153.27%
4.2%
3.1%
3 Years
7.19%
24.2%
17.1%

Highlights

Market Capitalization
916.1M
Book Value
- $0.11
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.17
PEG Ratio
2.97
Wall Street Target Price
12.06
Profit Margin
-4.28%
Operating Margin TTM
-0.43%
Return On Assets TTM
-0.46%
Return On Equity TTM
-15.91%
Revenue TTM
295.0M
Revenue Per Share TTM
2.58
Quarterly Revenue Growth YOY
21.5%
Gross Profit TTM
219.5M
EBITDA
2.5M
Diluted Eps TTM
-0.17
Quarterly Earnings Growth YOY
4.0
EPS Estimate Current Year
0.07
EPS Estimate Next Year
0.3
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
0.03

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Mimedx Group, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 59.42%

Current $7.57
Target $12.06

Company Financials

FY17Y/Y Change
Revenue
321.1M
↑ 31.07%
Net Income
64.7M
↑ 440.56%
Net Profit Margin
20.16%
↑ 15.27%
FY18Y/Y Change
Revenue
359.1M
↑ 11.82%
Net Income
-30.0M
↓ 146.32%
Net Profit Margin
-8.35%
↓ 28.51%
FY19Y/Y Change
Revenue
359.1M
↑ 0.0%
Net Income
-30.0M
↑ 0.0%
Net Profit Margin
-8.35%
↑ 0.0%
FY20Y/Y Change
Revenue
299.3M
↓ 16.67%
Net Income
-25.6M
↓ 14.67%
Net Profit Margin
-8.55%
↓ 0.2%
FY21Y/Y Change
Revenue
258.6M
↓ 13.58%
Net Income
-10.3M
↓ 59.79%
Net Profit Margin
-3.98%
↑ 4.57%
FY22Y/Y Change
Revenue
267.8M
↑ 3.57%
Net Income
-36.8M
↑ 257.58%
Net Profit Margin
-13.73%
↓ 9.75%
Q1 FY22Q/Q Change
Revenue
58.9M
↓ 12.63%
Net Income
-10.5M
↓ 573.54%
Net Profit Margin
-17.81%
↓ 21.1%
Q2 FY22Q/Q Change
Revenue
66.9M
↑ 13.57%
Net Income
-10.9M
↑ 3.61%
Net Profit Margin
-16.25%
↑ 1.56%
Q3 FY22Q/Q Change
Revenue
67.7M
↑ 1.21%
Net Income
-8.4M
↓ 22.47%
Net Profit Margin
-12.45%
↑ 3.8%
Q4 FY22Q/Q Change
Revenue
74.4M
↑ 9.88%
Net Income
-2.1M
↓ 74.96%
Net Profit Margin
-2.84%
↑ 9.61%
Q1 FY23Q/Q Change
Revenue
71.7M
↓ 3.63%
Net Income
-4.9M
↑ 131.33%
Net Profit Margin
-6.81%
↓ 3.97%
Q2 FY23Q/Q Change
Revenue
66.9M
↓ 6.69%
Net Income
-10.9M
↑ 122.66%
Net Profit Margin
-16.25%
↓ 9.44%
FY17Y/Y Change
Total Assets
121.3M
↓ 37.26%
Total Liabilities
47.5M
↓ 21.25%
FY18Y/Y Change
Total Assets
122.8M
↑ 1.31%
Total Liabilities
73.2M
↑ 54.22%
FY19Y/Y Change
Total Assets
122.8M
↑ 0.0%
Total Liabilities
73.2M
↑ 0.0%
FY20Y/Y Change
Total Assets
167.2M
↑ 36.08%
Total Liabilities
132.8M
↑ 81.4%
FY21Y/Y Change
Total Assets
187.9M
↑ 12.42%
Total Liabilities
95.4M
↓ 28.18%
FY22Y/Y Change
Total Assets
171.4M
↓ 8.78%
Total Liabilities
96.9M
↑ 1.65%
Q1 FY22Q/Q Change
Total Assets
174.4M
↓ 7.18%
Total Liabilities
89.4M
↓ 6.26%
Q2 FY22Q/Q Change
Total Assets
168.7M
↓ 3.31%
Total Liabilities
89.8M
↑ 0.44%
Q3 FY22Q/Q Change
Total Assets
172.8M
↑ 2.45%
Total Liabilities
99.8M
↑ 11.19%
Q4 FY22Q/Q Change
Total Assets
171.4M
↓ 0.79%
Total Liabilities
96.9M
↓ 2.91%
Q1 FY23Q/Q Change
Total Assets
168.2M
↓ 1.91%
Total Liabilities
93.6M
↓ 3.42%
Q2 FY23Q/Q Change
Total Assets
176.4M
↑ 4.89%
Total Liabilities
96.6M
↑ 3.14%
FY17Y/Y Change
Operating Cash Flow
62.9M
↑ 143.69%
Investing Cash Flow
-5.4M
↓ 53.78%
Financing Cash Flow
-60.4M
↑ 638.14%
FY18Y/Y Change
Operating Cash Flow
35.8M
↓ 43.13%
Investing Cash Flow
-9.2M
↑ 70.84%
Financing Cash Flow
-8.9M
↓ 85.21%
FY19Y/Y Change
Operating Cash Flow
35.8M
↑ 0.0%
Investing Cash Flow
504.0K
↓ 105.47%
Financing Cash Flow
-8.9M
↑ 0.0%
FY20Y/Y Change
Operating Cash Flow
-39.4M
↓ 210.1%
Investing Cash Flow
-4.6M
↓ 1003.77%
Financing Cash Flow
62.9M
↓ 803.59%
FY21Y/Y Change
Operating Cash Flow
-2.0M
↓ 94.97%
Investing Cash Flow
-3.4M
↓ 25.47%
Financing Cash Flow
-3.4M
↓ 105.33%
Q1 FY22Q/Q Change
Operating Cash Flow
-10.2M
↑ 216.31%
Investing Cash Flow
-148.0K
↓ 52.87%
Financing Cash Flow
-1.0M
↓ 4809.09%
Q2 FY22Q/Q Change
Operating Cash Flow
-3.0M
↓ 70.61%
Investing Cash Flow
-429.0K
↑ 189.86%
Financing Cash Flow
260.0K
↓ 125.1%
Q3 FY22Q/Q Change
Operating Cash Flow
959.0K
↓ 131.91%
Investing Cash Flow
-374.0K
↓ 12.82%
Financing Cash Flow
130.0K
↓ 50.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.0M
↓ 28.02%
Investing Cash Flow
-677.0K
-
Financing Cash Flow
-4.0K
↓ 106.06%

Technicals Summary

Sell

Neutral

Buy

Mimedx Group, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mimedx Group, Inc.
Mimedx Group, Inc.
5.73%
132.73%
153.27%
7.19%
25.4%
Moderna, Inc.
Moderna, Inc.
-12.64%
-32.32%
-18.59%
40.95%
434.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.2%
0.68%
18.02%
45.57%
106.06%
Novo Nordisk A/s
Novo Nordisk A/s
-2.18%
18.08%
84.58%
165.14%
289.05%
Seagen, Inc.
Seagen, Inc.
3.05%
4.69%
54.33%
11.57%
175.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.55%
11.62%
19.58%
30.6%
81.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mimedx Group, Inc.
Mimedx Group, Inc.
NA
NA
2.97
0.07
-0.16
0.0
0.0
-0.11
Moderna, Inc.
Moderna, Inc.
34.67
34.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.3
43.3
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.94
26.94
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mimedx Group, Inc.
Mimedx Group, Inc.
Buy
$916.1M
25.4%
NA
-4.28%
Moderna, Inc.
Moderna, Inc.
Buy
$37.3B
434.62%
34.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
106.06%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$410.6B
289.05%
43.3
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
175.61%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
81.41%
26.94
35.4%

Institutional Holdings

  • BlackRock Inc

    6.99%

  • Vanguard Group Inc

    5.33%

  • Paradigm Capital Management, Inc.

    3.00%

  • State Street Corporation

    2.90%

  • Geode Capital Management, LLC

    2.01%

  • Richmond Brothers Inc

    1.37%

Corporate Announcements

  • Mimedx Group, Inc. Earnings

    Mimedx Group, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.

Organization
Mimedx Group, Inc.
Employees
867
CEO
Mr. K. Todd Newton
Industry
Biotechnology

Discover More

FAQs